종양학 기반 In-Vivo CRO 시장

Global Oncology Based In-Vivo CRO Market to Reach US$1.7 Billion by 2032

The global market for Oncology Based In-Vivo CRO estimated at US$1.0 Billion in the year 2025, is expected to reach US$1.7 Billion by 2032, growing at a CAGR of 7.8% over the analysis period 2025-2032. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$882.1 Million by the end of the analysis period. Growth in the Blood Cancer segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$302.3 Million While China is Forecast to Grow at 7.5% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$302.3 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$309.0 Million by the year 2032 trailing a CAGR of 7.5% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Oncology Based In-Vivo CRO Market - Key Trends and Drivers Summarized

How Is Oncology Based In-Vivo CRO Supporting Cancer Research?

Oncology-based In-Vivo Contract Research Organizations (CROs) provide specialized services for preclinical testing of cancer therapies in live animal models. These CROs offer comprehensive in-vivo studies, including pharmacology, toxicology, and efficacy assessments, enabling pharmaceutical and biotech companies to evaluate the potential of new cancer drugs before clinical trials. By utilizing animal models that mimic human cancer conditions, CROs help researchers understand drug behavior, dosage optimization, and side effects. The growing complexity of cancer treatments, which now include immunotherapies, targeted therapies, and gene therapies, has increased the demand for specialized in-vivo studies to ensure safety and efficacy.

What Are the Key Segments in the Oncology Based In-Vivo CRO Market?

Key services include pharmacokinetics (PK), pharmacodynamics (PD), toxicology, and efficacy testing, with pharmacokinetics and pharmacodynamics being the most in-demand services due to their importance in early-stage drug development. The application segment covers different cancer types, such as lung cancer, breast cancer, colorectal cancer, and blood cancers, with lung and breast cancer studies accounting for a significant share due to their high prevalence and active drug development pipelines. Major end-users include pharmaceutical companies, biotechnology firms, and academic research institutions, all of which rely on in-vivo CROs to advance their oncology drug discovery efforts.

How Are In-Vivo CROs Integrated Into Oncology Research?

Pharmaceutical companies collaborate with in-vivo CROs to conduct preclinical testing for new cancer treatments, reducing the time and cost associated with drug development. These CROs offer tailored in-vivo models, including patient-derived xenografts (PDX), syngeneic models, and transgenic models, to accurately represent human tumor biology. Biotechnology firms, often focusing on novel therapies like CAR-T cells and bispecific antibodies, use in-vivo CROs for efficacy and safety evaluations before moving to clinical trials. Academic and research institutions also work with CROs to study the mechanisms of action of potential cancer therapies and identify promising drug candidates. The integration of advanced technologies, such as imaging tools and biomarker analysis, has enhanced the accuracy and relevance of in-vivo studies in oncology research.

What Factors Are Driving the Growth in the Oncology Based In-Vivo CRO Market?

The growth in the Oncology Based In-Vivo CRO market is driven by several factors, including the increasing prevalence of cancer, which has fueled demand for new therapies and accelerated drug development. The shift toward targeted and personalized treatments, such as immunotherapies and gene therapies, has necessitated the use of specialized in-vivo models that accurately mimic human tumors. Advancements in preclinical research tools, such as imaging techniques and biomarker analysis, have improved study accuracy and efficiency, supporting broader adoption. The rise in collaborations between CROs and biopharma companies, along with increased government funding for cancer research, has further contributed to market growth. Additionally, the growing number of biotech startups focused on innovative oncology therapies has boosted demand for in-vivo CRO services.

SCOPE OF STUDY:

The report analyzes the Oncology Based In-Vivo CRO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Solid Tumors, Blood Cancer, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Champion Oncology, Inc.
• Charles River Laboratory
• Covance
• Crown Bioscience
• Eurofins Scientific
• EVOTEC
• ICON Plc
• Living Tumor Laboratory
• MI Bioresearch, Inc.
• Taconic Biosciences
• The Jackson Laboratory
• Wuxi AppTec
• Xentech

WHAT SETS THIS REPORT APART FROM OTHERS?

Validated Sources - Human-curated validation and ranking of original source content, not AI LLM-generated synthetic content which dominates the internet today and has become a quick fix for most published research reports these days. Unlike most other published sources, our customers have access to full-stack source content. Our report draws from "real intelligence" balancing the power of AI against the risks of synthetically generated content and resulting biases. Customers have access to the source feeds.

Domain Expert Insights - Domain expert insights curated from enterprise, industry, academia, and government, consolidated from multilingual multimedia formats of text, voice, and images comprise a significant resource. Customers can request access to the pool of domain experts we track for this research project. We track 2,605 domain experts and their insights as part of this research project. Our customers may access our online tracker.

Annual subscription - Recommended for maximum value for your research dollar. Provides one additional full update during the 12 months and access to our research portal and interactive 10-user peer-to-peer collaboration drawing from our entire stack of validated project data which is updated on a weekly basis. Platform also enables adding enterprise data or third-party licensed content to build bespoke versions. Includes competitor tracking of up to 50 companies featured in the report.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Oncology Based In-Vivo CRO - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Cancer Research Spurs Growth in Oncology-Based In-Vivo CRO Market
  • Technological Advancements in Preclinical Models and Imaging Strengthen Business Case for Adoption
  • Growing Focus on Personalized Medicine and Immuno-Oncology Expands Addressable Market
  • Expansion of In-Vivo CROs in Drug Discovery, Translational Research, and Toxicology Fuels Market Growth
  • Increasing Adoption of In-Vivo Models in Target Validation, Biomarker Identification, and Efficacy Studies Expands Market Opportunities
  • Technological Innovations in Animal Models, Xenografts, and Patient-Derived Tumor Models Propel Market Expansion
  • Growing Use of In-Vivo CROs in Cell Therapy, Gene Therapy, and Antibody-Drug Conjugates (ADCs) Expands Market Potential
  • Focus on Achieving Faster Time-to-Market for New Therapies Strengthens Market for Oncology-Based In-Vivo CRO
  • Technological Advancements in High-Throughput Screening, Genomics, and Imaging Propel Market Growth
  • Increasing Focus on Integrating In-Vivo CROs with Big Data Analytics and Real-Time Monitoring Drives Adoption
  • Rising Demand for In-Vivo CRO Services in Immuno-Oncology, Radiotherapy, and CAR-T Therapy Strengthens Global Market
  • Expansion of Oncology-Based In-Vivo CROs in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 2: World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 3: World 13-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • TABLE 4: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 5: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 6: World 13-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 7: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 8: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 9: World 13-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 11: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 12: World 13-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 13: World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032

III. MARKET ANALYSIS

• UNITED STATES
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 15: USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 16: USA 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 18: Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 19: Canada 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• JAPAN
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 21: Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 22: Japan 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• CHINA
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 24: China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 25: China 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• EUROPE
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 27: Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 28: Europe 13-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 30: Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 31: Europe 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• FRANCE
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 33: France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 34: France 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• GERMANY
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 36: Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 37: Germany 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 39: Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 40: Italy 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• UNITED KINGDOM
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 42: UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 43: UK 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 46: Rest of Europe 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• ASIA-PACIFIC
  • Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 49: Asia-Pacific 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 51: Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 52: Rest of World 13-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2020, 2026 & 2032

IV. COMPETITION